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ABSTRACT  
Tobacco use is the single largest preventable risk factor for premature death of non-communicable 
diseases and the second leading cause of cardiovascular disease. In response to the harmful effects 
of tobacco smoking, the use of electronic cigarettes (e-cigarettes) has emerged and gained 
significant popularity over the last 15 years. E-cigarettes are promoted as safe alternatives for 
traditional tobacco smoking and are often suggested as a way to reduce or quit smoking. However, 
evidence suggests they are not harmless.  
The rapid evolution of the e-cigarette market has outpaced the legislator’s regulatory 
capacity, leading to mixed regulations. The increasing use of e-cigarettes in adolescents and young 
individuals is of concern. While the long-term direct cardiovascular effects of e-cigarettes remain 
largely unknown, the existing evidence suggest that the e-cigarette should not be regarded  as a 
cardiovascular safe product. The contribution of e-cigarette use to reduce conventional cigarette use 
and smoking cessation is complex and the impact of e-cigarette use on long-term cessation lacks 
sufficient evidence.   
This position paper describes the evidence regarding prevalence of e-cigarette smoking, 
uptake of e-cigarettes in the young, related legislations, cardiovascular effects of e-cigarettes, and 
impact of e-cigarettes on smoking cessation. Knowledge gaps in the field are also highlighted. The 
recommendations from the Population Science and Public Health Section of the European 
Association of Preventive Cardiology (EAPC) are presented.  
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INTRODUCTION  
Despite widespread population-based anti-smoking policies, 28% of the adult population (aged ≥15 
year) across Europe is still smoking.1 The use of electronic cigarettes (e-cigarettes) has emerged and 
gained significant popularity in response to the well-known harmful effects of tobacco smoking,2 
although their safety is questioned.3 The initial inception of the modern device is credited to Hon Lik, 
a Chinese pharmacist, who in 2003 discovered this method of vaping which gained a patent in 2007.4 
Overall, there are two main types of e-cigarettes: 1) disposable and rechargeable devices that look 
like cigarettes and 2) refillable vaporizers or tank systems that do not look like cigarettes.5  
E-cigarettes deliver a heated aerosol into the mouth and lungs. The main ingredients of e-cigarettes  
are propylene glycol and/or vegetable glycerine as carrier, and nicotine and flavors as the active 
substances.3  
In many countries e-cigarettes do not undergo the same strict regulations as conventional 
tobacco. Therefore, promotion via media and the internet is often allowed, reaching adults but also 
the young. Although the popularity of each type of e-cigarette can vary over time and between 
countries, what is universally recognized is that an increasing number of children, adolescents, and 
adults are utilizing e-cigarettes.6 E-cigarettes are promoted as safe alternatives for traditional 
tobacco smoking and are often suggested as a method to reduce or quit smoking. However, some 
evidence suggests they are not harmless.3, 7-10  
Hence, there is a need for an overview of the evidence for perceived benefits and harms of 
e-cigarettes. This position paper describes the prevalence of e-cigarette smoking, uptake of e-
cigarettes in the young, related legislations, cardiovascular effects of e-cigarettes, and impact of e-
cigarettes on smoking cessation in adults. Whilst our paper focuses on the cardiovascular effects of 
e-cigarettes, we are becoming increasingly aware of non-cardiac effects including the many cases of 
deaths associated with vaping and lung injury in the United States (US). The lung injury was 
associated with adding Vitamin E, which are likely to have a significant public health impact, but 
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remain outside the scope of our paper and hence not discussed in more detail.11 We do not review 
other adverse health effects in detail. We further highlight the knowledge gaps in the field. Finally, 
we present the recommendations from the Population Science and Public Health Section of the 
European Association of Preventive Cardiology (EAPC) concerning e-cigarette usage.  
 
PREVALENCE OF E-CIGARETTE SMOKING    
Prevalence of e-cigarette use is complex to define and three important aspects need to be 
considered. Firstly, definition of e-cigarette usage varies. Most studies in the literature describe ever 
use, that ranges from single-time experimentation to active, regular use and/or use in the past 7 or 
30 days  that is sometimes used as a surrogate of “current use”. Secondly, independent of definition,  
there is heterogeneity in prevalence across countries and sometimes even within a country. Thirdly, 
patterns of e-cigarette use evolve over time, with a rise in prevalence in more contemporary versus 
older surveys.12 Additionally, response to questionnaires may depend on type and order of the 
questions asked.13  
We have considered only the most recent prevalence data from 2015 to 2019. Older data 
can be found in several reviews.12, 14-18 Results are summarized in Table 1. Prevalence of ever use 
ranged from 0% (Egypt) to 56.6% (Lithuania); prevalence of past 30-day users ranged from 2.0% 
(Switzerland) to 35.0% (Poland), and prevalence of daily users ranged from 0.2% (Serbia) to 1.7% 
(USA). Dual use (i.e. e-cigarettes and classic cigarettes) ranged between 1.5% and 24.0% (both for 
Poland). Studies targeting youth or students consistently reported higher prevalence rates.   
 Overall, the available data show a wide variation in the prevalence of ever and current users 
between and even within countries. A plausible explanation is the role of the regional legislative and 
social environment in supporting or deterring e-cigarette use.19 The most consistent finding is the 
increasing prevalence of e-cigarette use in adolescents and young individuals.20 
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Knowledge gaps 
• Data on prevalence, determinants and motivations to use e-cigarettes in adolescents and 
young adults are lacking in many countries. 
• Prospective studies assessing the impact of occasional e-cigarette use on becoming a current 
e-cigarette user or a dual (e-cigarette and traditional tobacco) user are lacking. 
• There is little data available regarding trends in e-cigarette consumption and how people 
start with and quit e-cigarettes. 
 
UPTAKE OF E-CIGARETTES IN THE YOUNG 
E-cigarette use has shown an exponential expansion of uptake in the young, with studies reporting 
increase from 5% to up to 25% between 2013 and 2019. 20-22 (Figure 1)  
One of the main arguments supporting e-cigarette introduction and uptake was to help with 
smoking cessation. Whilst this might be a sensible argument for adults, its role in supporting 
smoking cessation in the young is less well defined.23 At the same time, while e-cigarette use might 
be safer compared to tobacco smoking, a worrying increase has been noted in the young who view 
e-cigarette as a new and safe «trend» and as a part of a «healthy life». Thus, e-cigarette can be 
easily taken up in the young without health-related considerations. There is a growing body of 
evidence that never-smoker minors who use e-cigarettes might double their chance of starting to 
smoke cigarettes later in life.24-27 The evidence is based on longitudinal observational studies, 
because randomized controlled trials to address this research question cannot ethically be 
performed due to the potential of causing harm.24-28 Flavors are important when we talk about 
children and adolescents. They prefer sweet flavors and they believe that sweet flavors are less 
harmful.29 Fruit, menthol or mint, and candy, desserts or other sweets are the most commonly 
reported flavors in e-cigarettes among youth. Therefore, these flavors should be banned.30   
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Furthermore, specific health related conditions in the young, including pregnancy and 
asthma, are adversely affected by e-cigarettes. There is actually no evidence proving e-cigarettes to 
be safe during pregnancy.31 Nicotine is harmful to the developing fetus and has several 
cardiovascular effects.32 Maternal active smoking, maternal passive smoking as well as paternal 
smoking all increase the risk of fetal congenital heart defects in offspring.33 Nicotine has been shown 
to increase placental vascular resistance and increase risk of hypertension throughout childhood and 
later in life. Possible mechanisms include endothelial injury, kidney abnormalities and increased 
cholesterol levels. Fetal nicotine exposure can impair the development of neurons and brain circuits 
and can increase the risk of preterm birth, stillbirth, and neonatal apnea.34 Likewise, e-cigarette use 
and secondary exposure have been linked with increased asthma attacks in the young.35 Moreover, 
there is circumstantial evidence that nicotine from e-cigarette use in the young might affect brain 
maturation leading to problems with cognition and emotional regulation later on in life, however 
more solid evidence for such a causative effect is awaited.36  
Similar to the conventional tobacco legislations, selling e-cigarettes to anyone under the age 
of 18 is illegal in many countries, but the legislation is often ignored. Further, the young often get or 
buy their supplies from relatives and friends or even directly from the stores and online. Where 
legal, e-cigarette advertising is a powerful inducer, with television advertising having the highest 
recall. Peer pressure and specialty retailer presence near schools may have an environmental 
influence of students’ e-cigarette experimentation, where it looks like an «adult candy store». 
Passive smoking from adults inside the same home and the tolerance of e-cigarettes at home in the 
young is also of concern.37-39  
E-cigarette is thus a new potential hazard for children and adolescents. Public health 
measures should thus be undertaken to minimize e-cigarette use in the young. The increased 
awareness and education of the young, in particular relating to the potential negative health effects 
of e-cigarette, should encourage better prevention and decrease in the use of e-cigarette, an 
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«epidemic of youth use».40 It is important to ensure minimal risk to the adverse effects of potential 
nicotine addiction.  
Knowledge gaps 
• There is an increasing use of e-cigarettes in the young. A growing body of evidence from 
longitudinal observational studies suggest that never-smoker minors who use e-cigarettes 
might double their chance of starting to conventional smoking later in life. Due to the ethical 
considerations and the potential of causing harm, data from randomized controlled trials on 
this matter are lacking. 
• Robust evidence regarding the influence of e-cigarettes on cognitive, visual and memory 
performances, and on attention among the youth is lacking. Similarly, no data exist 
regarding potential depressive effects and the influence of e-cigarettes on the quantity and 
the quality of sleep. 
 
LEGISLATION 
In 2016, the World Health Organization (WHO) submitted a report on e-cigarettes for the seventh 
session of the Conference of the Parties to the WHO Framework Convention on Tobacco Control 
(FTCT). WHO suggested regulatory measures to prohibit or restrict the manufacture, importation, 
distribution, presentation, sale and use of e-cigarettes, as appropriate to national laws and public 
health objectives.41 Also in 2016, the American Food and Drug Administration (FDA) issued a rule on 
tobacco products, including e-cigarettes. Products marketed for therapeutic purposes “to help people 
quit smoking” are regulated through the Center for Drug Evaluation and Research.42 In the EU, article 
20 of the Tobacco Products Directive (2014/40/EU) regulates e-cigarettes as consumer products, but 
allows EU Member States to classify e-cigarettes as medicines if conditions are fulfilled. The legislation 
that regulates manufacture, import, packaging, labelling, advertising, promotion, sale, and 
distribution, including components and parts was implemented in 2015, establishing a common 
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format for the notifications of e-cigarettes and refill containers and in 2016 regarding technical 
standards for the refill mechanism.  
Legislation regarding e-cigarettes is relatively new and there is no consensus on how to 
legislate the sales, packaging, taxes and public use. While most nicotine-dispensing e-cigarettes might 
be included under existing legislation regarding tobacco products, the legal fate of non-nicotine 
dispensing e-cigarettes is more complex. Two recent reviews43, 44 and one website45 summarize the 
existing data regarding legislation on e-cigarettes. Overall, legislation is available for 98 countries and 
varies considerably (Table 2 and Table 3).46 Even within a country such as the USA, regulations 
regarding e-cigarettes vary by state. The issue is further complicated by the fact that e-cigarettes can 
also be considered as consumer products or medicinal products. Worryingly, most African countries 
and populous countries such as India, Indonesia, China and Russia lack e-cigarettes regulation, 
although some improvements are under way.46 
Only 13 countries apply a tax to e-cigarettes.45 Twenty-nine countries ban e-cigarettes 
completely, and nine ban nicotine-containing liquids only (Table 3).46 It is almost impossible to give 
updated information, due to quick changes in legislation. Still, the ban of nicotine-containing liquids 
can be easily circumvented via internet imports or in shops due to lack of enforcement of the ban.47 
Many websites selling e-cigarette products perform no age checking and fail to provide any 
information regarding use or health warnings.48 Social media are utilized for promotional strategies 
and networking purposes, and social media influencers are brand ambassadors for e-liquid 
marketing.49 Finally, advertisements for devices resembling e-cigarettes as delivering “nutritional 
supplements” have been issued, leading consumers to believe that e-cigarettes are health-
enhancing.50 
Due to its relatively recent implementation, the effect of legislation on e-cigarette use has 
seldom been assessed. A US study suggested that higher excise taxes decrease e-cigarette purchases, 
while e-cigarette smoke-free laws do not affect e-cigarette purchases.51 Conversely, a study also 
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conducted in the US concluded that both higher prices and vaping restrictions are associated with less 
e-cigarette use.52 The recent outbreak of lung disease related to e-cigarettes has prompted several US 
states and countries to ban flavored e-cigarettes and to increase tax on non-flavored cigarettes, and 
the FDA to issue an enforcement policy regarding flavored e-cigarettes.8, 53  
The rapid evolution of the e-cigarette market has outpaced the legislator’s regulatory capacity, 
leading to mixed regulations and possibly illegal actions. Harmonization and implementation of 
existing regulations is necessary, as well as setting of swift procedures to adapt regulations and 
taxation to incoming evidence regarding the benefits and harms of e-cigarettes. Countries lacking a 
legal framework for e-cigarettes should rapidly create one.   
Knowledge gaps 
• There is no information at general population level regarding their acceptance of different 
measures to legislate e-cigarette use. 
• There is little if no evidence of the impact of different regulatory measures on the uptake and 
prevalence of e-cigarette use. 
• Longitudinal studies to understand the role of social media on e-cigarette use initiation 
among adolescent and young adult are needed. 
 
EFFECT OF E-CIGARETTES ON CARDIOVASCULAR FUNCTION AND CARDIOVASCULAR DISEASE  
While the association of conventional tobacco smoking with cardiovascular disease (CVD) is well 
established, research on the impact of e-cigarettes on CVD is limited. The harmful effects of tobacco 
are largely caused by the exposure to combustion products. There is substantial evidence that 
except for nicotine, under typical conditions of use, exposure to potentially toxic substances from e-
cigarettes is significantly lower compared with combustible cigarettes.54 Therefore, it is generally 
believed that the physiological effects of e-cigarettes are less harmful compared with tobacco 
cigarettes.54, 55 However, e-cigarettes do contain potential toxicants and exert a variety of biologic 
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effects,55 such that health-related sequelae linked to the exposure to nicotine as well as other 
components in the vapor produced by the devices cannot be excluded. Although nicotine-free e-
cigarette liquids are available, those containing nicotine are used much more commonly.  
Currently, direct evidence from clinical trials and long-term cohort studies regarding the 
clinical cardiovascular effects of e-cigarettes are not available and the consequences of their chronic 
use are largely unknown. The only available epidemiological evidence is based on the observational 
data from two studies. The National Health Interview Surveys of 2014 (N=36,697) and 2016 
(N=33,028) suggest an increased risk for myocardial infarction (MI) in e-cigarette users [odds ratio – 
OR (95% confidence interval – CI=1.79 (1.20, 2.66)], although to a lesser extent than conventional 
cigarette smoking [2.72(2.29, 3.24)].56  
In the absence of robust long-term evidence regarding the impact of e-cigarettes on CVD, 
only indirect estimates can be made. These are based on smoking cessation trials that used nicotine 
replacement therapies (NRT), or by estimating the levels of various known harmful substances in e-
liquid and vapor/aerosol, as well as by experimental animal and human studies and in-vitro studies 
investigating responses to exposure that are known to increase cardiovascular risk.  
A meta-analysis of 21 randomized trials including 11,647 patients (of which only 2 trials 
included patients with known CVD) found that NRT was associated with an increased risk of any 
cardiovascular event (driven by a higher risk of less-serious events, namely palpitations and 
arrhythmias) but not with a higher risk of major adverse cardiac events compared with placebo.57 In 
another meta-analysis of seven trials of NRT (all excluding individuals with known heart disease), 
only nausea was more common with active NRT vs. placebo.58 In contrast, some studies have shown 
that smokeless tobacco use is associated with increased incidence of fatal MI and higher mortality in 
patients with established coronary artery disease (CAD), suggesting that nicotine may contribute to 
acute (and potentially fatal) cardiovascular events in the presence of ischemic heart disease.59 Of 
note, because nicotine is absorbed more slowly from NRT delivery systems compared with the rapid 
absorption from conventional or e-cigarettes, and in view of slower absorption and lower peak 
 12 
 
nicotine levels in e-cigarette users compared with tobacco cigarette smokers, the results of NRT 
studies cannot be directly extrapolated to e-cigarette users. It should also be noted that the amount 
of nicotine delivered by e-cigarettes may vary substantially depending on several factors such as 
nicotine concentration in the e-cigarette liquid; user experience; puffing intensity; and device 
characteristics (less nicotine delivered by first-generation compared with more recent devices).  
 
The harmful cardiovascular effects of e-cigarettes have also been assessed indirectly, based 
on the documented toxicity of various constituents as well as on mechanistic studies investigating 
surrogate markers that are known to increase cardiovascular risk (Figure 2). A recent meta-analysis 
regarding hemodynamic effects of e-cigarettes included 14 non-randomized clinical studies of 
moderate quality (N=441 participants) among which 11 studies examined the acute effects of e-
cigarettes on the cardiovascular system (5–30 min after use) and 3 studies after switching from 
tobacco smoking to chronic e-cigarette use (mean time-point of assessment of 245 days).60 The 
meta-analysis showed that exposure to e-cigarettes acutely increased heart rate (HR), systolic and 
diastolic blood pressure (SBP and DBP). While switching from tobacco smoking to chronic e-cigarette 
use did not affect HR, it significantly reduced both SBP and DBP.60 Stimulation of atomized nicotine 
may also have a harmful long-term impact on vascular wall growth. In an observational study among 
24 young smokers in 4 different smoking scenarios, e-cigarette smoking increased arterial stiffness 
(measured by carotid-femoral pulse wave velocity) 5 min after use.60 Moreover, smoking e-cigarette 
for more than 30 minutes had an adverse effect on arterial stiffness that was similar to that of 
traditional cigarettes.60 However, e-cigarette use did not lead to increased arterial stiffness (assessed 
by photoplethysmography method and analysis of pulse wave graph) in another study.60 
Mechanistically, a single dose of e-cigarette aggravates endothelial cell dysfunction. Similar to 
conventional cigarettes, e-cigarettes have been shown to adversely affect endothelial function and 
decrease nitric oxide bioavailability. 61 Relative to cigarette smoking, e-cigarette use has been 
associated with a comparable and rapid increase in the number of circulating endothelial progenitor 
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cells, which could be attributed to acute endothelial dysfunction and/or vascular injury.60 Emerging 
evidence suggest that nicotine, irrespective of its source, could impair vascular function and lead to 
vascular calcification. With respect to myocardial function, one study assessing left ventricular 
diastolic function and strain found a delay in myocardial relaxation following acute smoking 
inhalation, but no significant effects in daily users of e-cigarettes. In a case-control study among 23 
apparently healthy, habitual e-cigarette users and 19 nonuser controls, habitual e-cigarette use (for 
at least 1 year) was associated with increased levels of oxidative stress and a shift in cardiac 
autonomic balance toward sympathetic predominance,62 both known to be associated with higher 
cardiovascular risk. In another investigation, acute exposure to e-cigarette containing nicotine was 
associated with increased cardiac sympathetic nerve activity compared with a sham control or non-
nicotine e-cigarette, in a pattern previously linked to increased cardiac risk.63 In addition to nicotine, 
other aerosol constituents that may exert adverse cardiovascular effects include oxidizing chemicals 
and particulate matter (PM).55 Fine and ultrafine particles (i.e., PM) are solid and liquid particles 
suspended in the air. PM with a diameter of ⩽2.5 µm can penetrate the airways and reach the 
circulation. Exposure to PM from ambient air pollution and tobacco smoking has been linked to 
higher risk of cardiovascular and all-cause mortality 64 It has been shown that PM are not only 
present in e-cigarette vapors, but are also exhaled in significant levels by e-cigarette users. Thereby, 
although direct evidence regarding cardiovascular consequences of e-cigarette-derived PM is 
missing, it is likely that e-cigarettes pose a potential risk to users and represent a source of second-
hand exposure to PM.  
The available indirect evidence regarding the cardiovascular effect of e-cigarettes is currently 
based mainly on non-randomized observational studies of small sample sizes, overall moderate 
quality, and short-term follow-up. A systematic review of cardiovascular effects from e-cigarettes 
included 38 studies. The review concluded that most studies suggest potential cardiovascular harm 
from e-cigarettes through mechanisms that increase risk of thrombosis and atherosclerosis.7 
Whether the described hemodynamic changes translate to a clinical risk of CVD remains uncertain, 
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and interpretation of these findings requires caution. Collectively, while the long-term 
cardiovascular effects of e-cigarettes remain largely unknown, the existing evidence suggest that the 
e-cigarette should not be regarded as a cardiovascular safe product.60 Moreover, on a population 
level, it is anticipated that the potentially “decreased” harm induced by e-cigarette (versus 
conventional tobacco smoking) may in part be offset by its increased use, in particular in more 
vulnerable populations such as the young.65 A nonlinear dose-response relationship exists between 
smoking and the risk of CVD and mortality, wherein light smoking (<3 cigarettes per-day), is 
associated with elevated rates of adverse health outcomes. Hence, it is hypothesized that increased 
e-cigarette use may ultimately not result in proportional harm reduction of cardiovascular mortality. 
At the population level, such adverse health effects are expected to increase by the widespread 
adoption of e-cigarette for both active smoking and smoking cessation. The long-term effects of 
ever-increasing e-cigarette use rates particularly in adolescents and youth, together with potential 
lag time effects upon attributable CVD and mortality rates, ought to be closely monitored and 
preemptively addressed by public health authorities. 
Knowledge gaps 
• Prospective studies assessing the effects of e-cigarettes on clinical cardiovascular outcomes 
are lacking.  
• Whether different patterns of e-cigarette smoking (with respect to age of onset, frequency, 
and cumulative duration of use) exert differential cardiovascular effects is largely unknown. 
 
EFFECTS OF E-CIGARETTES ON SMOKING CESSATION IN ADULTS 
E-cigarettes have been employed for facilitating smoking cessation attempts. However, their impact 
upon successful smoking cessation has not been comprehensively addressed to date. The most 
recent Cochrane Systematic Review66 analyzed 3 randomized clinical trials (RCTs) and 21 cohort 
studies (combined sample size=662) regarding the effect of e-cigarette use on smoking cessation. 
One RCT compared nicotine patches, nicotine-releasing e-cigarettes and nicotine-free e-cigarettes. 
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E-cigarettes, with or without nicotine, were modestly effective at helping smokers to quit, with 
similar achievement of abstinence as with nicotine patches.67 One-year abstinence rates were higher 
in the e-cigarette users (smokers not intending to quit) compared with users of non-nicotine e-
cigarettes in another RCT.68  The RCTs were deemed to be at low risk of bias, however overall quality 
of evidence was ‘low’ or ‘very low’ as a result of the small number of trials included.66 Since then, 
two other RCTs have been performed. In a pragmatic RCT including more than 6000 smokers, free e-
cigarettes were not superior to usual care or to free smoking cessation medication after one year.69 
On the other hand, a smoking cessation clinic based RCT found e-cigarettes to be more effective 
than NRT for smoking cessation, when both products were accompanied by intensive behavioral 
support. It is noteworthy that 80% of the study’s participants continued to use e-cigarettes for >12 
months.70 
RCTs are superior to observational studies with respect to internal validity. However, RCTs 
measure the relative effectiveness of e-cigarettes in specific groups of smokers under controlled 
circumstances. As e-cigarettes are readily available consumer products without clear instructions for 
use, observational studies could provide insight into the impact of e-cigarettes on smoking cessation 
as they are being used in real-world settings. The review of longitudinal studies regarding the impact 
of e-cigarette use on smoking cessation provides conflicting evidence.66 An older systematic review 
of observational studies and RCTs suggest that adequate nicotine replacement through more 
frequent use of  e-cigarette could reduce nicotine withdrawal symptoms and therefore lead to 
better smoking cessation rates.71 However, a meta-analysis of 15 longitudinal real-world studies 
assessing smoking in e-cigarette users compared with those who did not use e-cigarettes reported a 
negative association between e-cigarette use and cessation.72 A more recent cohort of young Swiss 
men, confirmed that e-cigarette use was not associated with beneficial smoking reduction and/or 
cessation effects at 15 months follow-up.73 An American natural environment observational study 
found that dual users of e-cigarettes and cigarettes were more likely than cigarette smokers to quit 
cigarettes in the short term at 6 months, but no more likely to quit cigarettes over time at 12 or 18 
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months.74 A large Italian survey comparing smoking abstinence rates for different quitting methods, 
showed that e-cigarette users were as likely to report abstinence as those using no aid but less likely 
to report abstinence than users of established quitting methods.75 
On the other hand, a recent nationwide sample of 1,400 college students showed that 
baseline e-cigarette users were more likely to report cessation of traditional cigarettes compared to 
non-users at 6-months’ follow-up.76 Further, a retrospective survey showed that current e-cigarette 
use was associated with increased past-12-month successful smoking cessation.77 On a population  
level, findings from an Italian cohort of e-cigarette users revealed that in the long-term those 
reverting to smoking outnumbered those who successfully ceased smoking.78 Evidence remains 
conflicting regarding the impact of e-cigarette use on long-term smoking cessation.79 
 Cumulatively, the available evidence seems insufficient to definitively answer the 
question of whether e-cigarettes help smokers to quit and remain smoke-free in the long term. 
Imprecision in measurement of e-cigarette exposure, inclusion of smokers not using e-cigarettes to 
quit, limited adjustment for confounding factors, and variable outcome measures of cessation are 
among the limitations of the current studies.80  
The current findings suggest that use of e-cigarettes for smoking cessation might increase 
abstinence rates in combination with behavioral therapy. The findings might suggest that e-
cigarettes ought to be implemented in a clinical setting as part of an intensive repeated counselling 
to have an effect but might undermine cessation for the clear majority of adult smokers who use e-
cigarettes outside a smoking cessation clinic. Additional studies of high quality and in particular 
pragmatic randomized trials are urgently needed. Such studies ought to incorporate the frequency 
of e-cigarette use upon successful long-term smoking cessation.  
Knowledge gaps 
• There is a lack of robust longitudinal data regarding the impact of e-cigarettes on smoking 
cessation. 
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RECOMMENDATIONS FROM THE EAPC POPULATION SCIENCE AND PUBLIC HEALTH SECTION  
1. Health professionals should be cautious in recommending use of e-cigarettes to their 
patients and the general public as: 1) mounting evidence suggests that e-cigarettes are 
harmful to health, including to the heart, 2) smokers might end up using e-cigarettes as a 
supplement to smoking without cutting back their tobacco consumption, 3) there is lack of 
robust evidence that e-cigarettes are effective as smoking cessation tool, 4) e-cigarettes 
seem to be used instead of evidence-based smoking cessation products and smoking 
cessation clinics. 
2. E-cigarette should only be considered to aid tobacco cessation alongside a formal tobacco 
cessation program.  
3. Decision makers should regulate e-cigarettes strongly or forbid their use as: 1) an epidemic 
rise in use of e-cigarettes among non-smoking adolescents has been observed in some parts 
of the world and we cannot rule out that this will spread to the rest of the world, 2) there is 
evidence that non-smoking children/youth using e-cigarettes might have an increased risk of 
uptake of smoking of conventional cigarettes, 3) at population level, it seems that e-
cigarettes may have an unfavorable net effect on smoking.  
4. Because of the rapidly evolving market, a regular update of the e-cigarette legislation is 
needed. Tobacco legislation revision, update and adaptation is needed in countries with 
legislation written before e-cigarettes came on the market.  
5. There should be strict regulation of e-cigarette marketing and advertising to youth. E-
cigarette marketing and advertising in public places, all media, internet and social media 
should be governed by the same regulations as for tobacco with particular aim to protect 
the young. Strong age verification procedures are needed to prevent adolescents from 
accessing tobacco and e-cigarettes websites. 
6. Similar to traditional cigarette smoking, abstinence of e-cigarette during pregnancy should 
be recommended. 
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7. Awaiting further scientific research, caution is needed when consuming e-cigarettes. Hence, 
the population should be made aware of potential adverse effects. Media and social media 
campaigns with effective messages/testimonials should be utilized to prevent initiation of 
new e-cigarette smokers. In particular, the knowledge of the negative effects of e-cigarette 
should be included during specific healthy lifestyle education programs at school.  
8. Government and non-government funding should be encouraged to support ethically and 
appropriately designed research investigating multiple subclinical and clinical effects of e-
cigarette smoking on various systems, including the cardiovascular system.   
9. Researchers should apply standardized methodologies in studies assessing surrogate or 
clinical effects of e-cigarettes to allow direct comparisons between the studies.  
10. Countries should be encouraged to follow the WHO Framework Convention on Tobacco 
Control (FCTC). 
 
CONCLUSIONS  
The prevalence of e-cigarette smoking is increasing, particularly in the young, and evidence suggests 
that this will increase likelihood of conventional smoking. Some studies have found e-cigarettes to 
have harmful cardiovascular effects but more studies, in particular on long-term effects of e-
cigarettes on cardiovascular outcomes are needed. Currently, there is a lack of robust longitudinal 
data on the impact of e-cigarettes on smoking cessation, and more research is warranted. 
Nonetheless, health professionals should inform their patients and the general public of the possible 
cardiovascular and other risks of e-cigarette smoking. Continued monitoring and legislation to limit 
use is important.  
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FIGURE LEGENDS  
Figure 1. Longitudinal trend in e-cigarette and tobacco use in pupils aged 11-18 years in the United States 
between 2011 and 2018.  
 
Figure 1. Data used with permission from Cullen KA, Ambrose BK, Gentzke AS et al.  Notes from the field: use 
of electronic cigarettes and any tobacco product among middle and high school students - United States, 2011-
2018. MMWR Morb Mortal Wkly Rep. 2018;67:1276-7.20 
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TABLES 
 
Table 1. Prevalence e-cigarette consumption, stratified by WHO region and country, among studies conducted from 2015 onwards. 
 
Country/Reference Study 
period 
Setting Sample size Age Results 
Americas      
Brazil 81  2015 Students of the Federal University of Mato 
Grosso 
489 NR 2.7% ever users 
0.61% current users 
      
Canada 82 2014-2015 Canadian Student Tobacco, Alcohol and Drugs 
Survey (336 schools from 128 school boards) 
42,094 NR 17.7% ever users 
5.7% past 30-day users 
      
Canada 83 2015 Canadian Tobacco Alcohol and Drugs 15,154 15+ 13.2% ever users 
3.2% past 30-day users 
0.8% daily users 
      
Mexico 84 2015 Stratified random sampling of schools in 
Mexico City, Guadalajara, and Monterrey 
10,146 12-13 10% ever users 
      
Mexico 85 2016 National Survey of Drugs, Alcohol and Tobacco 
Use 
12,436 12-17 7.0% ever users 
1.1% current users 
      
Mexico 85 2016 National Survey of Drugs, Alcohol and Tobacco 
Use 
36,966 
non-smokers 
18+ 3.0% ever users 
0.3% current users 
      
Mexico 85 2016 National Survey of Drugs, Alcohol and Tobacco 
Use 
7,347 
smokers 
18+ 18.0% ever users 
5.0% dual users 
      
USA 86 2014-2015 Tobacco Use Supplement- Current Population 
Survey 
225,413 18+ 9.4% (rural) and 7.0% (urban) ever users 
2.8% (rural) and 2.1% (urban) current 
users 
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USA 87 2015  
 National Youth Tobacco Survey 
17,711 <18 4.8% (middle school) and 12.8% (high 
school) past 30-day users 
USA 88 2015 Tobacco Products and Risk Perceptions Survey 6,008 18+ 17.0% ever users 
7.4% current users 
1.7% daily users 
      
USA 89 2015 Health Information National Trends Survey 3,738 18+ 22.4% ever users 
      
USA 90 2016 Behavioral Risk Factor Surveillance System 466,842 18+ 4.5% current users 
1.5% daily users 
      
USA 91 2016 Behavioral Risk Factor Surveillance 
System 
477,665 18+ 16.2% (DC) to 28.4% (Arkansas) ever 
users 
2.4% (DC) to 6.7% (Oklahoma) current 
users 
      
USA 92 2016 National Health Interview Survey 32,931 18+ 15.3% ever users 
3.2% current users 
      
USA 93-95 2018 Monitoring the Future 13,850 NR Past 30-days users 
25.0% (12th grade) 
20.3% (10th grade) 
8.1% (8th grade) 
Eastern 
Mediterranean 
     
Egypt 96 2015 Cross-sectional community survey 1239 15-75 0% ever users 
      
Saudi Arabia 97 Nov-Dec 
2017 
Three universities in Jeddah 1007 15+ 27.7% ever users 
4.1% daily users 
4.4% mixed smoker/vaper 
Western Pacific      
Australia 98 Feb 2016 New South Wales 3,188 18+ 13.0% ever users 
4.0% past 30-day users 
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0.5% daily users 
      
China 99 2015 Mobile app-based survey 2,042 12-18 26.4% ever users 
      
Japan 100 2015 Japan "Society and New Tobacco" Internet 
Survey 
8,240 15-69 1.3% past 30-day users 
      
Korea 101 2015 middle and high school students from Seoul, 
Incheon, Gyeonggi, and Cheongju 
2,744 13-18 12.6% ever users 
6.3% past 30-day users 
4.9% past 30-day dual users 
      
Korea 101 2015 University students from fourteen universities 2,167 19-29 21.2% ever users 
7.2% past 30-day users 
5.9% past 30-day dual users 
      
Malaysia 102 2016 National E-cigarette survey 4,288 18+ 11.9% ever users 
3.2% current 
2.3% dual users 
      
New Zealand 103, 
104 
2016 Health and Lifestyles Survey 3,854 15+ 17.0% ever users 
1.8% current users 
1.0 daily users 
      
Taiwan 105 2014-2016 Taiwan Global Youth Tobacco Survey NR 12-18 3.1% past 30-day users 
1.6% dual users 
      
Taiwan 106 2015 Adult Smoking Behavior Survey. 26,021 15+ 2.7% ever users 
      
Europe      
Belarus 107 2017-2018 University students 3,895 19.3±2.1 42.7% ever users 
2.7% current users 
2.0% dual users 
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France 108 2014-2015 Cross-sectional study on two major campuses 1,134 20.8 years 23.0% ever users 
5.7% current users 
Germany 109 2015 Epidemiological Survey of Substance Abuse 9,204 18-64 14.3% ever users 
2.9% past 30-day users 
2.1% dual users 
      
Germany 110 2016 Representative surveys on substance use 
conducted by the Federal Center for Health 
Education 
2,462 18-25 7.6% (male) and 3.4% (female) past 30-
day users5 
      
Germany 110 2016 Representative surveys on substance use 
conducted by the Federal Center for Health 
Education 
2,459 12-17 4.2% (male) and 2.5% (female) past 30-
day users5 
      
Germany 111 2016 Random sample 4,002 14+ 11.8% ever users 
1.4% regular users 
      
Greece 112 2017 adults living in Attica prefecture 4,058 18+ 27.2% ever users 
5.0% current use 
      
Lithuania 107 2017-2018 University students 1,128 19.8±1.3 56.6% ever users 
3.5% current users 
2.1% dual users 
      
Poland 70 2015-2016 National Adult Tobacco Survey 1,978 15-19 35.0% past 30-day users 
24.0% past 30-day dual users 
 
Poland 107 2017-2018 University students 7,324 21.9±2.1 45.0% ever users 
2.8% current users 
1.5% dual users 
      
Russia 48 2015 Students of the Republic of Bashkortostan 716 15+ 28.6% ever users 
2.2% past 30-day users 
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Russia 107 2017-2018 University students 1,290 20.4±2.2 33.4% ever users 
4.0% current users 
2.6% dual users 
Serbia 113, 114 December 
2017 
three stage, random, nationally representative 
survey 
1,045 18+ 10.7% ever users 
0.2% daily users 
      
Slovakia 107 2017-2018 University students 715 22.5±1.8 34.4% ever users 
2.3% current users 
2.6% dual users 
      
Spain 115 2015 Sistema de Información sobre Conductas de 
Riesgo 
7,908 15+ 5.3% ever users 
0.7% current users 
      
Spain 116 2015-2016 Students of the University of Almeria 745 21.9±3.9 22.5% ever users 
2.5% current users 
1.7% daily users 
      
Sweden 117 2016 Schools of the Scania region 13,835 14-21 9th grade 
32% (males) and 27% (females) ever 
users 
10.8% (males) and 7.0% (females) 
past 30-day users 
2nd grade 
43% (males) and 31% (females) ever 
users 
11.1% (males) and 5.0% (females) 
past 30-day users 
      
Switzerland 118 July-Dec 
2015 
Continuous Rolling Survey of Addictive 
Behaviours and Related Risks 
5,252 15+ 14.0% ever users 
2.0% past 30-day users 
0.3% daily users 
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The Netherlands 
119 
2014-2015 19 secondary schools randomly selected 
across the Netherlands 
6,819 11-17 With nicotine 
13.7% ever users 
6.7% past 30-day users 
Without nicotine 
29.4% ever users 
13.2% past 30-day users 
      
The Netherlands 
119 
2016-2017 Traditional and Novel Substance use among 
Adolescents study 
2,758 14-21 With nicotine 
12.3% ever users 
2.5% past 30-day users 
Without nicotine 
27.6% ever users 
2.6% past 30-day users 
      
UK (Wales) 120 2015 87 Secondary schools in Wales. 32,479 11-16 18.5% ever users 
1.4% daily users 
      
UK 121 2015-2016 Smoking Toolkit Study 81,063 16+ 5.5% current users 
      
UK 106 2015-2017 The Youth Tobacco Policy Survey; the Schools 
Health Research Network Wales survey; two 
Action on Smoking and Health (ASH) 
Smokefree Great Britain-Youth Surveys; and 
the Scottish Schools Adolescent Lifestyle and 
Substance Use Survey 
60,201 11-16 7% to 32% ever users 
1% to 3% weekly users 
      
 
Only studies conducted from 2015 to 2018 are included in this table.  
Current use is defined as either daily or occasionally.  
Abbreviations: NR, not reported.  
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Table 2. Details of the legislation regarding e-cigarettes, as of April 2019. Countries who have a complete ban are not represented. 
 
Country Advertising Minimum age 
Child proof 
packaging  
Health warning 
label 
Nicotine 
vol./concentr. 
Vape-free 
public places 
Europe       
Austria, Belgium, Bulgaria,  
Croatia, Cyprus, Denmark,  
Estonia, Finland, France,  
Germany, Italy, Lithuania,                Yes                           Yes                        Yes                          Yes                        Yes                          Yes  
Luxembourg, Poland,  
Portugal, Slovakia,  
Slovenia, Spain 
  
Czech Republic, Greece,                    
Netherlands, Sweden,                        Yes                           Yes                        Yes                          Yes                        Yes                           
United Kingdom 
       
Malta Yes  Yes Yes  Yes Yes 
Ireland, Latvia, Romania Yes 
 
Yes Yes Yes  
Georgia  Yes  Yes  Yes 
Norway Yes Yes     
Hungary, Iceland, Serbia Yes      
Azerbaijan, Ukraine  
    
Yes 
Belarus, Bosnia &  
Herzegovina, FYR                                    -                             -                             -                               -                              -                                -    
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Macedonia, Israel,  
Switzerland 
 
Africa 
      
   South Africa - - - - - - 
   Togo Yes Yes 
   
Yes 
Americas       
   Barbados, Jamaica  
    
Yes 
   Canada, Mexico Yes 
    
 
   Chile - - - - - - 
   Costa Rica, Ecuador, Haiti,   
Hunduras  
Yes Yes 
   
Yes 
   USA Yes Yes Yes Yes 
 
 
   Venezuela  Yes 
    
Yes 
South-East Asia, Eastern Mediterranean, Western Pacific  
   Australia Yes 
    
Yes 
   Fiji, Republic of Korea, 
   Viet Nam 
Yes Yes 
   
Yes 
   Japan, New Zealand  Yes 
    
 
   Malaysia  Yes     
   Philippines  
 
Yes 
  
Yes 
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   DPR Korea, Tunisia,       
   China,Hong Kong 
- 
- 
- 
- - 
- 
-, no data available. Empty cell indicates no such topic.  
Countries are categorized according to the WHO geographical areas, with a further division for European countries. 43-45  
Advertising: most countries include advertising, promotion or sponsorship of all types of e-cigarettes, while others restrict advertisement of nicotine-
containing e-cigarettes; minimum age is usually set at 18 years, with some exceptions (i.e. 16 years for Belgium and 19 years in the Republic of Korea); child 
proof packaging: in the EU, packages should also be tamper-proof and have a mechanism that allows refilling without spillage to protect consumers; health 
warnings: usually indicating that the product contains nicotine, which is an addictive product; nicotine volume or concentration: in the EU, maximum 
concentration is 20 mg/mL; vape-free public places: vaping in vehicles with minors and/or pregnant women is also prohibited in several countries. 
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Table 3. Available legislation regarding e-cigarettes.  
  
Product classification 
 
Country Legislation Tobacco-related product Other Sales 
European Union     
Austria 
Existing, amended 
& new 
Tobacco-related product 
Medicinal, medical device, 
consumer good 
Authorization required 
Belgium Existing 
 
Medicinal, consumer good Authorization required 
Bulgaria    Authorization required 
Croatia Existing Tobacco (imitation) 
Consumer good, chemical 
product 
Authorization required 
Cyprus    Authorization required 
Czech Republic Existing Tobacco (imitation) 
Medicinal, consumer good, 
hazardous substance 
Authorization required 
Denmark Existing & new E-cigarette Medicinal Authorization required 
Estonia New 
Tobacco-related product 
E-cigarette 
 Authorization required 
Finland New 
Tobacco (imitation), tobacco-
related product, E-cigarette 
Medicinal Authorization required 
France Existing & amended E-cigarette Medicinal, consumer good Authorization required 
Germany New 
Tobacco-related product 
E-cigarette 
Consumer good Authorization required 
Greece Amended Tobacco-related product Consumer good Authorization required 
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E-cigarette 
Hungary Amended 
 
Consumer good Authorization required 
Ireland Existing & new E-cigarette Medicinal, consumer good Authorization required 
Italy Amended 
Tobacco-related product 
E-cigarette 
 Authorization required 
Latvia New 
Tobacco-related product 
E-cigarette 
 Authorization required 
Lithuania New 
Tobacco-related product 
E-cigarette 
 Authorization required 
Luxembourg Existing 
 
Poison, electrical appliance Authorization required 
Malta Legal notice 
Tobacco-related product 
E-cigarette 
 Authorization required 
Netherlands Existing 
Tobacco-related product 
E-cigarette 
Medicinal, consumer good Authorization required 
Poland New  
 
Chemical mixture, Consumer 
good 
Authorization required 
Portugal Existing E-cigarette  Authorization required 
Romania    Authorization required 
Slovakia Amended Tobacco 
Tobacco-free product 
intended to smokers 
Authorization required 
Slovenia    Authorization required 
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Spain Amended ENDS  Permitted, regulated 
Sweden    Authorization required 
Europe, other     
Azerbaijan    Permitted, regulated 
Belarus    Permitted, regulated 
Bosnia & Herzegovina    Permitted, regulated 
FYR Macedonia    Permitted, regulated 
Iceland Existing 
 
Medicinal, consumer product Permitted, regulated 
Israel    Permitted, regulated 
Georgia    Permitted, regulated 
Norway Existing 
Tobacco surrogate 
E-cigarette 
Medicinal Authorization required 
Serbia     Permitted, regulated 
Switzerland Existing E-cigarette Consumer good Nicotine ban 
Turkey Amended Tobacco, e-cigarette  Complete ban 
Turkmenistan    Complete ban 
Ukraine Amended E-cigarette  Permitted, regulated 
United Kingdom Existing & new E-cigarette Medicinal, consumer good Authorization required 
Africa     
Gambia    Complete ban 
Mauritius Existing Tobacco (imitation)  Complete ban 
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Seychelles Existing Tobacco (imitation)  Complete ban 
South Africa Ruling 
 
Medicinal Authorization required 
Togo New Tobacco (derivative)  Permitted, regulated 
Uganda    Complete ban 
Americas     
Argentina Existing ENDS, tobacco  Complete ban 
Barbados    Unknown 
Brazil Decree; resolution E-cigarette, tobacco  Complete ban 
Canada Existing 
 
Drug, consumer good Nicotine ban 
Chile Resolution 
 
Medicinal Unclear 
Colombia Existing Tobacco (imitation)  Complete ban 
Costa Rica Existing ENDS, tobacco (derivative)  Nicotine ban 
Ecuador Existing ENDS, tobacco (derivative)  Permitted, regulated 
El Salvador Decree E-cigarette   
Haiti Existing Tobacco (derivative)  Unclear 
Honduras    Permitted, regulated 
Jamaica Existing & amended ENDS Medicinal Nicotine ban 
Mexico Existing Tobacco (imitation)  Nicotine ban 
Nicaragua Existing Tobacco (imitation)  Complete ban 
Panama Decree ENDS, tobacco (imitation)  Complete ban 
Suriname New ENDS  Complete ban 
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USA New Tobacco product  Permitted, regulated 
Uruguay Amendment/decree Electronic smoking device  Complete ban 
Venezuela  Existing Tobacco (derivative) Medicinal, consumer good Permitted, regulated 
South-East Asia     
DPR Korea    Permitted, regulated 
Nepal Notification ENDS  Complete ban 
Thailand Existing 
Tobacco (imitation) 
E-cigarette 
‘Modern’ medicinal Complete ban 
Eastern Mediterranean     
Bahrain Existing ENDS, tobacco  Complete ban 
Iran Amended Tobacco product  Complete ban 
Jordan Official letter E-cigarette  Complete ban 
Kuwait Decision E-cigarette  Complete ban 
Lebanon Decision E-cigarette  Complete ban 
Oman Decision E-cigarette  Complete ban 
Qatar Circular; decision E-cigarette  Complete ban 
Saudi Arabia Decision E-cigarette  Complete ban 
Syria Circular E-cigarette  Complete ban 
Tunisia    Authorization required 
United Arab Emirates Decision E-cigarette  Complete ban 
Western Pacific 
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Australia Existing 
 
Poison, consumer good Nicotine ban 
Brunei Darussalam Existing Tobacco (imitation) Poison Complete ban 
Cambodia Circular E-cigarette  Complete ban 
China    Permitted, regulated 
Fiji Amended  E-cigarette  Authorization required 
Hong Kong    Permitted, regulated 
Japan Existing 
 
Medicinal Nicotine ban 
Malaysia    Nicotine ban 
New Zealand Existing Tobacco Medicinal, consumer good Nicotine ban 
Philippines Order 
 
Medicinal, medical device Authorization required 
Republic of Korea Existing & amended Tobacco Consumer good Unclear 
Singapore Existing Tobacco (imitation)  Complete ban 
Timor-Leste New E-cigarette  Complete ban 
Viet Nam Existing Tobacco  Permitted, regulated 
ENDS, electronic nicotine delivery systems. Countries are categorized according to the WHO geographical areas, with a further division for European 
countries.43-45 
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Figure 1. Longitudinal trend in e-cigarette and tobacco use in pupils aged 11-18 years in the United States between 2011 and 2018. 
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Figure 2. Existing evidence on the cardiovascular effects of e-cigarettes. 
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